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Looking Beyond Surveillance, Epidemiology, and End Results
Patterns of Chemotherapy Administration for Advanced Non-small
Cell Lung Cancer in a Contemporary, Diverse Population
Drew W. Rasco, MD,* Jingsheng Yan, PhD,† Yang Xie, PhD,† Jonathan E. Dowell, MD,*
and David E. Gerber, MD*
Introduction: Chemotherapy prolongs survival without substan-
tially impairing quality of life for medically fit patients with ad-
vanced non-small cell lung cancer (NSCLC), but population-based
studies have shown that only 20 to 30% of these patients receive
chemotherapy. These earlier studies have relied on Medicare-linked
Surveillance, Epidemiology, and End Results (SEER) data, thus ex-
cluding the 30 to 35% of lung cancer patients younger than 65 years.
Therefore, we determined the use of chemotherapy in a contemporary,
diverse NSCLC population encompassing all patient ages.
Methods: We performed a retrospective analysis of patients diag-
nosed with stage IV NSCLC from 2000 to 2007 at the University of
Texas Southwestern Medical Center. Demographic, treatment, and
outcome data were obtained from hospital tumor registries. The
association between these variables was assessed using univariate
analysis and multivariate logistic regression.
Results: In all, 718 patients met criteria for analysis. Mean age was
60 years, 58% were men, and 45% were white. Three hundred
fifty-three patients (49%) received chemotherapy. In univariate anal-
ysis, receipt of chemotherapy was associated with age (53% of
patients younger than 65 years versus 41% of patients aged 65 years
and older; p  0.003) and insurance type (p  0.001). In a
multivariate model, age and insurance type remained associated with
receipt of chemotherapy. For individuals receiving chemotherapy,
median survival was 9.2 months, compared with 2.3 months for
untreated patients (p  0.001).
Conclusions: In a contemporary population representing the full age
range of patients with advanced NSCLC, chemotherapy was admin-
istered to approximately half of all patients—more than twice the
rate reported in some earlier studies. Patient age and insurance type
are associated with receipt of chemotherapy.
KeyWords: Non small-cell lung cancer, Chemotherapy, Metastatic,
Practice patterns, Insurance.
(J Thorac Oncol. 2010;5: 1529–1535)
Chemotherapy has a well-defined role in the treatment ofmedically fit patients with advanced non-small cell lung
cancer (NSCLC). Compared with best supportive care, che-
motherapy prolongs overall survival without substantially
impairing quality of life.1–5 Nevertheless, population-based
studies from the 1990s have shown that only 22 to 31% of
patients with advanced NSCLC ever receive chemotherapy
during the course of their disease.6–8 Potential reasons for this
seemingly low treatment rate include advanced patient age, poor
performance status, and comorbidities; referring and treating
physician practice patterns; and patient preference.9
Even considering these factors, these earlier studies
may have underestimated current rates of treatment for ad-
vanced NSCLC. First, these studies used Medicare-linked
Surveillance, Epidemiology, and End Results (SEER) data
and therefore included only patients aged 65 years and
older.6–8 In the United States, more than 30% of individuals
with lung cancer are younger than 65 years.10 Second, most
of these studies reported data from the 1990s, a time frame
that may not reflect contemporary practice patterns. Over the
past 10 years, advances in diagnosis, treatment, and support-
ive care may have expanded the patient population consid-
ered for cancer-directed therapy. For example, increased use
of positron emission tomography scans has resulted in earlier
detection of extrathoracic disease, conceivably leading to
diagnosis of advanced-stage NSCLC earlier in the clinical
course, when patients may be more medically fit to receive
chemotherapy.11 In addition, the number of therapies for
NSCLC has grown in recent years, including relatively well-
tolerated agents such as erlotinib and pemetrexed. Adminis-
tration of these and other therapies has been enhanced by
improved antiemetics and more convenient formulations of
hematopoietic growth factors.
Given these considerable changes to the clinical care of
patients with NSCLC, as well as the absence of data on the
substantial proportion of individuals younger than 65 years,
we performed a single-institution study encompassing a di-
verse population diagnosed with stage IV NSCLC from 2000
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to 2007. Based on the considerations described above, we
hypothesized that this cohort would have higher rates of
chemotherapy administration than those previously reported.
MATERIALS AND METHODS
Study Setting
This study was approved by the University of Texas
Southwestern Medical Center at Dallas (UT Southwestern)
Institutional Review Board. The study sample was drawn
from UT Southwestern-associated clinical facilities, includ-
ing Parkland Health and Hospital System (PHHS), University
Hospital, and the Harold C. Simmons Cancer Center. PHHS
consists of a 968-bed public hospital and outpatient clinics
that provide care to primarily indigent and uninsured resi-
dents of Dallas County. University Hospital (415 beds) serves
as the primary medical and surgical referral hospital for UT
Southwestern. The Simmons Cancer Center is a freestanding
outpatient diagnostic and treatment facility. All three sites are
located in Dallas, Texas.
Dallas County is the eighth most populous county in the
United States, with an estimated 2.4 million residents in 2008
of whom 39% were Hispanic, 35% were white, and 21% were
African American.12
Data Extraction
Patients diagnosed with stage IV NSCLC between
January 1, 2000, and December 31, 2007, were identified
through UT Southwestern-associated tumor registries. The
2000–2007 time period was selected because (1) sufficient
data were first recorded by the tumor registries in 2000 and
(2) the 2007 cutoff provided sufficient follow-up time for
survival outcomes. Patient data were obtained from the
PHHS and UT Southwestern tumor registries. The tumor
registries identify cases through review of pathology records,
clinic schedules, and hospital admission and discharge
records. Certified tumor registrars abstract data directly from
the patients’ medical records, according to standards estab-
lished by the American College of Surgeons Commission on
Cancer, SEER/National Cancer Institute, and the National
Program of Cancer Registries. More than 150 data fields are
collected per patient, including demographics, cancer diag-
nosis and stage, treatment, and follow-up. After initial cancer
diagnosis and treatment, the tumor registries contact patients
and their medical providers every 6 months to obtain fol-
low-up data. These data are then reported to the Texas State
Cancer Registry and to the Commission on Cancer’s National
Cancer Database.
Recording and Definition of Variables
For each subject, the following data were recorded: age,
gender, race, insurance type, date of diagnosis, whether or not
chemotherapy was administered, and date of last known
follow-up or death. Race was categorized as white, Hispanic,
African American, or other. Insurance type was recorded as
one of the following: no insurance, Medicaid (a federal/state
health care program for low-income families), Medicare (a
federal health care program for individuals aged 65 years and
older), and private insurance. The designation “no insurance”
predominantly includes individuals ultimately treated under a
county health plan that provides patients access to all diag-
nostic and treatment modalities within PHHS. Overall sur-
vival was defined as the interval between date of diagnosis
and date of death.
Statistical Analysis
Descriptive statistics (medians/means for continuous
variables and percentages for discrete variables) were gener-
ated for baseline demographic and clinical characteristics.
Both univariate and multivariate logistic regression models
were used to explore the association between baseline char-
acteristics, year of diagnosis, and receipt of chemotherapy. In
these analyses, age was dichotomized as younger than 65
years and 65 years and older; year of diagnosis was dichot-
omized as 2000–2003 and 2004–2007. In the multivariate
model, we included subject age, gender, race, insurance type,
and year of diagnosis. These predictive variables were iden-
tified without using any model selection methods. We ana-
lyzed the association between baseline patient characteristics,
year of diagnosis, receipt of chemotherapy, and overall sur-
vival using univariate and multivariate Cox regression.
Again, no model selection methods were specified in the
multivariate model. All reported p values are two sided.
All statistical analyses were performed using SAS 9.1
Service Pack 4 for Windows (SAS Institute Inc., Cary, NC).
RESULTS
Study Population
A total of 718 patients met criteria for analysis. Gender,
race, and year of diagnosis were available for all patients.
Insurance type was available for 697 patients (97%). Median
follow-up was 5.0 months, and 679 patients (95%) were
followed until death. The mean patient age was 60 years;
58% were men and 45% were white. Additional baseline
patient characteristics are listed in Table 1.
Chemotherapy Administration
Overall, 353 patients (49%) received chemotherapy. In
univariate analysis (Table 2), age was associated with receipt
of chemotherapy (p  0.003). Among patients younger than
65 years, 53% received chemotherapy, compared with 41%
of those aged 65 years and older. Insurance type was also
associated with chemotherapy administration (p  0.001).
Among individuals with private health insurance, 60% re-
ceived chemotherapy, compared with 57% of those with
Medicaid, 45% of those with Medicare, and 40% of those
with no insurance. Subject gender, race, and year of diagnosis
were not significantly associated with receipt of chemother-
apy. Forty-seven percent of men received chemotherapy and
52% of women received chemotherapy (p 0.23). There was
a nonsignificant trend toward increased use of chemotherapy
for white patients (53%) compared with non-white patients
(46%) (p  0.09). The rate of chemotherapy administration
by year of diagnosis ranged from 42% in 2001 to 55% in
2006, but no clear trend was apparent (Figure 1).
In multivariate analysis (Table 2), patient age and insur-
ance type remained significantly associated with chemotherapy
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administration. Compared with older individuals, patients
younger than 65 years were more likely to receive chemotherapy
(odds ratio 1.96; 95% confidence interval, 1.26–3.06; p 
0.003). Compared with individuals with private insurance, those
with no insurance were less likely to receive chemotherapy
(odds ratio 0.44; 95% confidence interval 0.30–0.64; p 
0.001). Subject gender, race, and year of diagnosis were not
associated with receipt of chemotherapy.
Survival Analysis
Median survival for all patients was 5.0 months. In
univariate analysis (Table 3), overall survival was associated
with subject gender (p  0.02), insurance type (p  0.01),
and receipt of chemotherapy (p  0.001) but was not asso-
ciated with age, race, or year of diagnosis. Median overall
survival for men was 4.6 months, compared with 5.9 months
for women. Patients with private health insurance had a
median survival of 6.1 months versus a median survival of
4.2 months for patients with no insurance. Patients who
received chemotherapy had a median survival of 9.2 months
versus 2.3 months for untreated patients (see Figure 2). In
multivariate analysis (Table 3), survival remained signifi-
cantly associated with gender (p  0.04) and receipt of
chemotherapy (p  0.001) but was no longer associated with
insurance type (p  0.23).
DISCUSSION
To our knowledge, this is the first study to examine
chemotherapy use for advanced NSCLC in a contemporary
population encompassing the full age range of this disease. In
this setting, approximately half of all patients received chemo-
therapy, more than twice the rate reported in some earlier series.7
Chemotherapy administration was associated with patient age
and insurance status. Specifically, younger patients and those
with private health insurance were more likely to receive che-
motherapy. Median overall survival was fourfold longer among
individuals who received chemotherapy.
Whether the higher rate of chemotherapy administra-
tion in this cohort reflects the inclusion of all patient ages, the
contemporary era of the study, the particular practice patterns
of clinicians at our institution, or other factors is not clear.
The mean age in our study sample was 60 years, a full decade
younger than the mean age of NSCLC diagnosis in the United
States. That stated, more than 40% of patients aged 65 years
and older received chemotherapy, a rate still considerably
higher than that reported in prior studies. Because tumor
registry data at UT Southwestern is limited before 2000, the
impact of study era on our findings is not readily determined.
Although higher than previously reported, the 49%
treatment rate in this series of patients with advanced NSCLC
is still lower than treatment rates for other common malig-
nancies. For example, a recent population-based study in
Canada found that 63% of patients with metastatic colon
cancer receive chemotherapy13; at least 70 to 80% of patients
with breast and prostate cancer receive systemic therapy.14
Several factors may explain the lower likelihood of lung
cancer patients receiving treatment. With a median age at
diagnosis of 71 years, they are older than patients with breast
(median 61 years) and prostate (median 68 years) cancer.10 In
contrast to breast and prostate cancer, there are no hormonal
therapeutic options, which are generally more easily admin-
istered and better tolerated than conventional cytotoxic che-
motherapy. Furthermore, many physicians may not be aware
of the growing evidence in support of chemotherapy for
advanced NSCLC. Wassenaar et al.9 found that primary care
physicians are less likely to refer patients with advanced lung
cancer to an oncologist, compared with patients with ad-
vanced breast cancer. In that study, only 31% of primary care
physicians were aware that chemotherapy improves survival
in advanced lung cancer. Once NSCLC patients are referred
to cancer specialists for treatment, relatively low response
rates may limit recommendations for chemotherapy. In two
landmark phase III trials comparing various chemotherapy
regimens for advanced NSCLC, the highest response rates
ranged from 22 to 35%.15,16 In analogous trials for other
malignancies, chemotherapy response rates were 61 to 74%
for breast cancer17–19 and 45 to 53% for colon cancer.20–23
In this study, chemotherapy administration was signif-
icantly associated with patient age and insurance type. Forty-
one percent of patients aged 65 years and older received
chemotherapy, compared with 53% of patients younger than
65 years. When one considers that older patients are more
likely to have comorbidities and/or poor performance status,
this finding is not surprising. Indeed, it was recently shown
that older patients with advanced NSCLC are more likely to
suffer chemotherapy-associated adverse events, despite a
lower likelihood of receiving (potentially more toxic) plati-
num-based regimens.24
TABLE 1. Baseline Patient Characteristics
Characteristics
Total number 718










No insurance 271 (38)
Medicaid 46 (6)
Medicare 179 (25)








Values are given as n (%) or mean  SD.
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To our knowledge, the lower rate of chemotherapy
receipt among underinsured patients with advanced NSCLC
has not been previously reported but is consistent with a
number of earlier observations in this disease. It has been
shown that insured patients with NSCLC are more likely to
be diagnosed with early-stage disease,25 to have surgery for
early-stage disease,26 and to receive timely treatment after
diagnosis.27 Furthermore, patients with stages I to IIIA
NSCLC who were dually eligible for Medicare and Med-
icaid (a socioeconomically disadvantaged group) had in-
ferior survival compared with patients with Medicare.28
Thus, socioeconomic status can have far-reaching effects
throughout the disease course of patients with NSCLC, a
finding also noted in other malignancies, including breast
and colorectal cancer.29,30
In our cohort, explanations for this association are not
clear. Although we previously reported longer diagnostic and
treatment intervals for stage I to III NSCLC in our safety-net
medical system, these intervals were not associated with
clinical outcomes.27 Indeed, it seems unlikely that treatment
selection would differ by medical facility within our institu-
tion, because the same clinicians care for lung cancer patients
at all sites. Furthermore, the various facilities have similar
treatment options, including state-of-the art chemotherapy,
biologic agents, and supportive medications, and these are
available to patients regardless of insurance status through
safety-net medical programs. However, as we have previ-
ously reported,27 other aspects of care, such as treatment
delays, do differ among UT Southwestern-associated facili-
ties, and these factors may ultimately impact the administra-
FIGURE 1. Chemotherapy administration for
stage IV non-small cell lung cancer (NSCLC) by
year (2000–2007).
TABLE 2. Association Between Subject Characteristics and Administration of Chemotherapy
Patient
Characteristics
Univariate Analysis Multivariate Analysis
Odds Ratio for








65 yr 1.62 1.18–2.22 1.96 1.26–3.06
65 yr Reference Reference
Gender 0.23 0.43
Male Reference Reference
Female 1.20 0.89–1.62 1.13 0.83–1.54
Race 0.09 0.37
White Reference Reference
Non-white 0.77 0.58–1.04 0.87 0.64–1.18
Insurance type 0.001 0.001
No insurance 0.46 0.31–0.65 0.001 0.44 0.30–0.64 0.001
Medicaid 0.86 0.45–1.64 0.65 0.80 0.41–1.54 0.50
Medicare 0.55 0.36–0.82 0.004 0.85 0.51–1.41 0.53
Private insurance Reference Reference
Year of diagnosis 0.37 0.51
2000–2003 Reference Reference
2004–2007 1.14 0.85–1.53 1.11 0.82–1.51
CI, confidence interval.
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tion of chemotherapy. It has also been shown that there are
wide variations in attitudes toward chemotherapy among
patients with NSCLC, although the association between these
attitudes and demographic characteristics such as socioeco-
nomic status remains unclear.31
Although we presumed that treatment of advanced
NSCLC may be increasing over time, within the time period
of our study, chemotherapy administration was not signifi-
cantly associated with the year of diagnosis. Nevertheless, as
shown in Figure 1, 2 of the 3 years in which chemotherapy
was given to more than 50% of patients were the last 2 years
of the study period (2006 and 2007), which may suggest a
recent upward trend. The last 10 years have seen substantial
advances in the medical management of advanced NSCLC.
In the area of supportive care, darbepoetin (Food and Drug
Administration approved in 2001) and PEG-filgrastim (ap-
FIGURE 2. Association between chemother-
apy administration and survival.
TABLE 3. Association Between Subject Characteristics and Overall Survival
Patient Characteristics
Univariate Analysis Multivariate Analysis
Hazard Ratio








65 yr 1.02 0.87–1.20 1.23 0.99–1.53
65 yr Reference Reference
Gender 0.02 0.04
Male Reference Reference
Female 0.84 0.72–0.98 0.85 0.72–0.99
Race 0.53 0.94
White Reference Reference
Non-white 1.05 0.90–1.22 0.99 0.85–1.16
Insurance type 0.001 0.23
No insurance 1.38 1.14–1.67 0.001 1.08 0.89–1.32 0.44
Medicaid 1.21 0.87–1.68 0.28 1.18 0.84–1.65 0.33
Medicare 1.25 1.02–1.54 0.04 1.29 1.00–1.66 0.05
Private insurance Reference Reference
Year of diagnosis 0.45 0.33
2000–2003 Reference Reference
2004–2007 1.06 0.91–1.24 1.08 0.93–1.27
Chemotherapy administration 0.001 0.001
Yes Reference Reference
No 2.64 2.26–3.08 2.81 2.38–3.31
CI, confidence interval.
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proved in 2002) have markedly simplified the administration
of hematopoietic growth factors, and aprepitant (approved in
2003) has improved prevention of nausea and vomiting.
Since 2004, the anticancer therapies bevacizumab, erlotinib,
and pemetrexed have been approved for advanced NSCLC,
drugs notable for their relative tolerability. Indeed, from 1997
to 2002, chemotherapy administration for patients aged 65
years and older with advanced NSCLC increased from 28 to
36%.32 Whether the developments in the 2000s will lead to a
further increase in treatment rates is not yet known.
Median survival in this study was 5.0 months, and
receipt of chemotherapy was the only factor associated with
survival in multivariate analysis. The median survival for
patients treated with chemotherapy was 9.2 months, similar to
other studies.5,16 However, at 2.3 months, median survival for
the 51% of patients who did not receive chemotherapy was
considerably lower than that in previous reports. In pivotal
phase III clinical trials demonstrating the benefit of chemo-
therapy for advanced NSCLC, the median survival of patients
randomized to best supportive care alone ranged from 4.0 to
5.7 months.1,3 Our observational, nonrandomized study per-
mits no conclusions to be drawn about the effectiveness of
chemotherapy, because the patients who did and did not
receive chemotherapy differed in several measured and un-
measured ways.
Nevertheless, our outcome data may provide insight
into reasons why patients did not receive chemotherapy. That
overall survival among chemotherapy-treated patients in our
series approximates survival reported in prospective clinical
trials suggests that the performance status and organ function
of these individuals may be roughly similar to those of trial
participants. By contrast, the particularly poor survival
among untreated patients in our cohort suggests that these
individuals differ from patients who were eligible for the
trials of chemotherapy versus supportive care; they are likely
to have a worse performance status, more comorbidities, and
impaired organ function. Thus, although there are several
reasons why patients may not receive chemotherapy, includ-
ing patient preference, access to care, and provider prefer-
ence, it seems reasonable to conclude that insufficient med-
ical fitness was a driving factor in our study. Accordingly, it
is possible that insurance type, a widely used socioeconomic
marker, is also serving as a surrogate for overall medical
condition. Separately, the finding that overall survival seems
shorter in multivariate analysis for younger patients in this
cohort (hazard ratio for death  1.23; p  0.06) merits
comment. Although this study offers no certain explanation,
we believe that this observation may reflect the characteristics
of our particular lung cancer patient population in which
younger individuals are more likely to come from socioeco-
nomically disadvantaged groups.27
This study has a number of limitations. Perhaps most
importantly, the patient sample is drawn from a single aca-
demic medical center, limiting the generalizability of our
findings. That stated, because of our geographic setting and
the variety of UT Southwestern-associated clinical facilities,
our patient cohort is racially and socioeconomically diverse.
Second, this is a retrospective analysis and therefore subject
to bias from incomplete data availability. However, as evi-
denced by follow-up through death for more than 95% of
patients in the cohort, it seems that the tumor registries have
successfully captured the clinical and therapeutic course of
these patients. As mentioned, this study does not provide
specific reasons why chemotherapy was not administered to
half of all patients, and this remains a critical question for
lung cancer clinicians and researchers alike. In addition, we
do not have data on which treatments were administered.
Finally, because of the process by which cases are coded by
the tumor registries, our cohort does not include patients with
recurrent, metastatic disease after treatment for early-stage
NSCLC or patients with malignant pleural effusions, who are
typically treated with an advanced disease paradigm but until
recently were categorized as stage IIIB.
In conclusion, in this contemporary, diverse cohort of
patients with advanced NSCLC, approximately half of all
patients receive chemotherapy. Chemotherapy administration
is associated with patient age and insurance type, a relation-
ship that may reflect patients’ underlying medical condition.
Among patients who did not receive chemotherapy—most
likely because of lack of medical fitness for treatment—
overall survival was approximately 2 months. It is hoped that
future developments in this field increase not only treatment
efficacy but also the proportion of patients able to benefit
from them.
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